Clinical Account Manager responsible for the commercial launch of AQNEURSA™ (levacetylleucine) for the treatment of neurological manifestations of Niemann-Pick Disease Type C (NPC) in adult and pediatric patients weighing ≥15 kg. Responsible for 14 States in the Southern USA (FL, GA, SC, NC, TN, KY, KS, MO, OK, TX, LA, AR, MS, AL)

Bile Acid Portfolio Acquired by Mirum Pharmaceuticals from Travere Therapeutics in September 2023.Rare diseases Senior Clinical Account Manager responsible for Cholbam, an ultra-orphan product indicated for Bile Acid Synthesis Disorders due to single enzyme defects, Cerebrotendinous Xanthomatosis and as adjunctive treatment of liver manifestations in peroxisomal disorders including Zellweger Spectrum Disorders. Call points include academic and community based Pediatric Transplant Hepatologists, Gastroenterologists, Neurologists, Lipidologists, Ophthalmologists and Metabolic & Clinical Geneticists in multiple States in the Southeast USA (FL, GA, AL, SC, LA, MS).2021 - Ranked #2 in Country - CAPSTONE Award Winner / President's Club2021 - Promoted to Senior Clinical Account Manager in initial wave of field sales promotions2020 - Ranked #2 in Country - CAPSTONE Award Winner / President's Club2019 - Ranked #3 in Country2018 - Ranked #2 in Country - CAPSTONE Award Winner / President's Club2017 - Ranked #3 in Country

Formerly Questcor Pharmaceuticals, Acquired by MallinckrodtActhar sales - Orphan & Rare Diseases DivisionRheumatology & Neuromuscular diseases - Polymyositis/Dermatomyositis, Systemic Lupus Erythematosus, Psoriatic Arthritis, Rheumatoid Arthritis, Sarcoidosis

Formerly Questcor Pharmaceuticals, Acquired by MallinckrodtNational Sales Trainer - Orphan & Rare Diseases DivisionResponsible for all sales related training for Rheumatology & Neuromuscular diseases Polymyositis/Dermatomyositis, Systemic Lupus Erythematosus, Psoriatic Arthritis, Rheumatoid Arthritis, Sarcoidosis

Formerly Questcor Pharmaceuticals, Acquired by MallinckrodtActhar Specialist - Orphan & Rare Diseases Division2012 MVP Award2013 #9 in the Country2014 Promoted to National Training ManagerRheumatology & Neuromuscular diseases - Polymyositis/Dermatomyositis, Systemic Lupus Erythematosus, Psoriatic Arthritis, Rheumatoid Arthritis, Sarcoidosis

Sales of Rituxan (Rituximab) for Rheumatoid Arthritis, Wegener's Granulomatosis, and Microscopic Polyangiitis in the Rheumatology, Nephrology, and Oncology infusion marketManagement Development Graduate - rated promotable now

Sales force eliminated January 2011, Rituxan promotion taken over by Genentech.Multiple Regional, National, & Peer awards. Management Development Graduate - rated promotable nowResponsible for the sales and market share growth of Rituxan (Rituximab), a monoclonal antibody, 5 hour Intravenous Infusion dosed in 6 month intervals for the treatment of refractory Rheumatoid Arthritis in the Hospital Infusion Setting, Out-Patient Infusion Center, or Office Based Infusion Suite. Field Development Manager responsible for field and classroom based sales training.2010: Ranked # 1 of 64 representative; Number 1 Rep in Country; 153% to plano 4 Time Sales Excellence Award winnero Field Development Manager / Field Sales Trainero Graduated Cornerstone Management Development Program; completed October 2010o Commercial IT Infrastructure Development Team2009: Ranked #3 of 64 Representatives; Top 5%, 122% to plano Leadership Circle National Award Winnero 4 time Sales Excellence Awardo Sales Consistency Award (All 4 Quarters at 101% or above)o #3/64 in Ramp it Up Sales Contest for Market Share Growtho Selected Region MVP 2009, Peer Awardo Promoted to Senior ABM (ABM 3), Appointed Field Development Managero Advisor to 2 initial sales training classes, 1 advanced training class2008: 32/64; 102% - Significantly increased vial count, share, and growth rate

Diabetes sales, Byetta & Symlin

Diabetes & Cardiovascular Care Sales